Open Access

Immune checkpoints and immunotherapy in non‑small cell lung cancer: Novel study progression, challenges and solutions (Review)

  • Authors:
    • Lin-Rui Ma
    • Jia-Xin Li
    • Ling Tang
    • Run-Ze Li
    • Jia-Shun Yang
    • Ao Sun
    • Elaine Lai‑Han Leung
    • Pei-Yu Yan
  • View Affiliations

  • Published online on: September 14, 2021     https://doi.org/10.3892/ol.2021.13048
  • Article Number: 787
  • Copyright: © Ma et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Lung cancer is the most common type of cancer with the highest mortality rate worldwide. Non‑small cell lung cancer (NSCLC) accounts for ~85% of the total number of lung cancer cases. In the past two decades, immunotherapy has become a more promising treatment method than traditional treatments (surgery, radiotherapy and chemotherapy). Immunotherapy has been shown to improve the survival rate of patients and to have a superior effect when controlling lung cancer than traditional therapy. However, only a small number of patients can benefit from immunotherapy, and not all patients who qualify experience long‑term benefits. In the clinic, the objective response rate of programmed cell death protein 1 treatment without the prior screening of patients is only 15‑20%. Immunotherapy is associated with both opportunities and challenges for patients with NSCLC. The current challenges of immunotherapy include the lack of accurate biomarkers, inevitable resistance and insufficient understanding of immune checkpoints. In previous years, several methods for overcoming the challenges posed by immunotherapy have been proposed, but combination therapy is the most suitable choice. A large number of studies have shown that the combination of drugs can significantly improve their efficacy, compared with monotherapy, and that some therapeutic combinations have been approved by the Food and Drug Administration for the treatment of NSCLC. Traditional Chinese medicine (TCM) is a traditional medical practice in China that can play an important role in immunotherapy. Most agents used in TCM originate from plants, and have the advantages of low toxicity and multiple targets. In addition, TCM includes a unique class of drugs that can improve autoimmunity. Therefore, TCM may be a promising treatment method for all types of cancer.
View Figures
View References

Related Articles

Journal Cover

November-2021
Volume 22 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ma L, Li J, Tang L, Li R, Yang J, Sun A, Leung EL and Yan P: Immune checkpoints and immunotherapy in non‑small cell lung cancer: Novel study progression, challenges and solutions (Review). Oncol Lett 22: 787, 2021.
APA
Ma, L., Li, J., Tang, L., Li, R., Yang, J., Sun, A. ... Yan, P. (2021). Immune checkpoints and immunotherapy in non‑small cell lung cancer: Novel study progression, challenges and solutions (Review). Oncology Letters, 22, 787. https://doi.org/10.3892/ol.2021.13048
MLA
Ma, L., Li, J., Tang, L., Li, R., Yang, J., Sun, A., Leung, E. L., Yan, P."Immune checkpoints and immunotherapy in non‑small cell lung cancer: Novel study progression, challenges and solutions (Review)". Oncology Letters 22.5 (2021): 787.
Chicago
Ma, L., Li, J., Tang, L., Li, R., Yang, J., Sun, A., Leung, E. L., Yan, P."Immune checkpoints and immunotherapy in non‑small cell lung cancer: Novel study progression, challenges and solutions (Review)". Oncology Letters 22, no. 5 (2021): 787. https://doi.org/10.3892/ol.2021.13048